Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Array Biopharma IncfiledCriticalAstrazeneca Ab
Priority to UY29539ApriorityCriticalpatent/UY29539A1/en
Publication of UY29539A1publicationCriticalpatent/UY29539A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se revelan inhibidores de Mek en el tratamiento de enfermedades hiperproliferativas, tales como cáncer e inflamación, en mamíferos, y condiciones inflamatoias. También se revelan métodos de usar tales compuestos en el tratamiento de enfermedades hiperproliferativas en mamíferos y composiciones farmacéuticas que contienen esos compuestos.Mek inhibitors are revealed in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing those compounds are also disclosed.
UY29539A2006-05-172006-05-17
MEK HETEROCICLIC INHIBITORS AND SAME USE METHODS
UY29539A1
(en)
Compounds derived from isoindolones; pharmaceutical composition comprising them; and its use as mek kinase inhibitors to treat hyperproliferative and / or inflammatory diseases such as cancer, rheumatoid arthritis among others.
Compounds derived from substituted nicotinamide; pharmaceutical composition that includes them; use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
Heterocyclic derived compounds, cb2 modulators; pharmaceutical composition comprising them; and use in the treatment of rheumatic, autoimmune, inflammatory diseases, pain, among others.
Compounds derived from 5-alkynyl-pyrimidines, kinase inhibitors; pharmaceutical compositions containing them; and its use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
Compounds derived from halogenoalkyl-1,3-oxazines substituted, inhibitors of bace1 and / or bace2; procurement procedure; pharmaceutical composition that includes them; its use in the treatment and / or prophylaxis of diseases such as diabetes, Alzheimer's, als, autoimmune inflammatory diseases, cancer, among others.
Compounds derived from purine with immunomodulatory activity; pharmaceutical composition comprising them; and use of them in the treatment of allergic diseases, allergic rhinitis, asthma, infectious diseases and cancer.
Nitrogen heterocycle derived compounds, gamma secretase modulators; pharmaceutical composition comprising them; and its use in the treatment of neurodegenerative diseases such as Alzheimer's, Down syndrome; pharmaceutical kit.
Compounds derived from substituted phenylamino-benzene; Preparation method; pharmaceutical composition; farm kit; and use of said compounds in the treatment of cancer.
Compounds derived from pyrimidine, tyrosine kinase inhibitors; pharmaceutical compositions comprising them; and its use in the treatment and / or prevention of cancer, inflammatory diseases and autoimmune diseases.
Compounds derived from phenylamino-isonicotinamide; mek inhibitors; Pharmaceutical composition and use for the treatment of hyperproliferative diseases such as cancer and inflammation.
Compounds derived from narcyclasin and pancratistatin; preparation procedure; pharmaceutical composition; pharmaceutical combination; and its use for the treatment of cancer.